Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2007, Vol. 5 ›› Issue (1): 5-10.doi: 10.3736/jcim20070102

Special Issue: Traditional Chinese Medicine

• Commentary • Previous Articles     Next Articles

An optimized 3-step strategy for preventing and treating post-operation relapse and metastasis of malignant tumors with traditional Chinese medicine

Zhen-ye Xu, Zhan Zheng   

  1. Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, and Institute of Oncology, Shanghai Academy of Traditional Chinese Medicine, Shanghai 200032, China
  • Online:2007-01-31 Published:2007-01-21

Relapse and metastasis are the main causes responsible for failure of surgical operation in treating malignant tumors. This article introduces the present development in post-operation treatment of lung cancer, liver cancer and stomach cancer, showing that the synthetic treatment by stages combined with traditional Chinese medicine is the important way to prevent and treat the post-operation relapse and metastasis of tumors, and suggesting the optimized method for treatment.

Key words: traditional Chinese medicine, tumors, relapse, metastasis

CLC Number: 

  • R730.1
[1] 汤钊猷 . 现代肿瘤学(第2版)[M]. 上海: 上海医科大学出版社, 2000,( 第2版):254
Tang ZY. Modern oncology(2nd ed)[M]. Shanghai: Shanghai Medical University Press, 2000,( 2nd ed):254
[2] 徐振晔, 杨宇飞 . 肺癌中西医综合治疗(第1版)[M]. 北京: 人民卫生出版社, 2002,( 第1版):541
Xu ZY, Yang YF. Comprehensive treatment of lung cancer with traditional Chinese and Western medicine(1st ed)[M]. Beijing: People's Medical Publishing House, 2002,( 1st ed):541
[3] Tanaka F, Wada H . Efficacy of postoperative adjuvant therapy for resected non-small cell lung cancer--an evidence-based review[J]. Gan To Kagaku Ryoho, 2006,33(3):300-306
[4] Uramoto H, Kagami S, Iwashige A , et al. Chemotherapy for lung cancer patients[J]. J UOEH, 2006,28(1):75-84
doi: 10.7888/juoeh.28.75 pmid: 16541742
[5] Schiller JH, Harrington D, Belani CP , et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer[J]. N Engl J Med, 2002,346(2):92-98
[6] Barlesi F, Jacot W, Astoul P , et al. Second-line treatment for advanced non-small cell lung cancer: a systematic review[J]. Lung Cancer, 2006,51(2):159-172
doi: 10.1016/j.lungcan.2005.08.017 pmid: 16360238
[7] Hanna N . Advances in the treatment of second-line non-small-cell lung cancer[J]. Lung Cancer, 2005,50(Suppl 1):S15-S17
doi: 10.1016/S0169-5002(05)81554-5 pmid: 16291425
[8] De Marinis F, De Santis S, De Petris L . Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies[J]. Semin Oncol, 2006,33(1 Suppl 1):S17-S24
[9] Zinner RG, Fossella FV, Gladish GW , et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer[J]. Cancer, 2005,104(11):2449-2456
[10] Dowell JE . Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact[J]. Am J Med Sci, 2006,331(3):139-149
[11] Herbst RS, Giaccone G, Schiller JH , et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial--INTACT 2[J]. J Clin Oncol, 2004,22(5):785-794
[12] Giaccone G, Herbst RS, Manegold C , et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial--INTACT 1[J]. J Clin Oncol, 2004,22(5):777-784
[13] Belvedere O, Grossi F . Lung Cancer Highlights from ASCO 2005[J]. Oncologist, 2006,11(1):39-50
doi: 10.1634/theoncologist.11-1-39 pmid: 16401712
[14] Belani CP, Ramalingam S . Bevacizumab extends survival for patients with nonsquamous non-small-cell lung cancer[J]. Clin Lung Cancer, 2005,6(5):267-268
[15] Tyagi P . Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: preliminary results from the ECOG 4599 trial[J]. Clin Lung Cancer, 2005,6(5):276-278
[16] Bruix J, Llovet JM, Castells A , et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution[J]. Hepatology, 1998,27(6):1578-1583
[17] Pelletier G, Ducreux M, Gay F , et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC[J]. J Hepatol, 1998,29(1):129-134
[18] 汤钊猷 . 汤钊猷临床肝癌学(第1版)[M]. 上海: 上海科技教育出版社, 2001,( 第1版):123
Tang ZY. Tang Zhaoyou clinical hepatocarcinology(1st ed)[M]. Shanghai: Shanghai Scientific and Technical Education Publishing House, 2001,( 1st ed):123
[19] Kretzschmar A, Schlag PM . Efficacy of current adjuvant and neoadjuvant therapeutic concepts in gastric cancer?[J]. Zentralbl Chir, 2006,131(2):121-125
doi: 10.1055/s-2006-921537 pmid: 16612778
[20] Kodera Y, Fujiwara M, Koike M , et al. Chemotherapy as a component of multimodal therapy for gastric carcinoma[J]. World J Gastroenterol, 2006,12(13):2000-2005
doi: 10.1111/j.1365-2036.2006.02866 pmid: 16610047
[21] Papakostas P, Tsavdaridis D, Kosmidis P , et al. Combination docetaxel(Taxotere), fluorouracil, and leucovorin(TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group phase II study[J]. Gastric Cancer, 2006,9(1):26-31
doi: 10.1007/s10120-005-0353-4
[22] 张秀良, 徐淑峰, 徐鹏 , 等. 晚期胃癌姑息性术后腹腔热灌注化疗联合静脉化疗与单纯静脉化疗的临床观察[J]. 临床肿瘤学杂志, 2006,11(1):43-45
Zhang XL, Xu SF, Xu P , et al. The study of intraperitoneal hyperthermic chemotherapy and intravenous chemotherapy after palliative operation for patients with advanced gastric carcinoma[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2006,11(1):43-45
[23] 林黎明, 陈军, 苏妍 , 等. 胃癌术后腹腔热灌注化疗的临床应用[J]. 山东医药, 2005,45(16):35-36
doi: 10.3969/j.issn.1002-266X.2005.16.017
Lin LM, Chen J, Su Y , et al. Clinical application of continuous hyperthermic peritoneal perfusion chemotherapy after operation for gastric carcinoma[J]. Shandong Yi Yao, 2005,45(16):35-36
[24] 严桂英, 徐振晔, 王中奇 , 等. 中药抗瘤增效方对非小细胞肺癌化疗增效减毒作用的临床研究[J]. 中华实用中西医杂志, 2005,18(6):873-876
Yan GY, Xu ZY, Wang ZQ , et al. A clinical study on the synergic effect of chemotherapy combined with traditiona1 Chinese medicine Kangliu Zengxiao Fang in treatment of advanced non-small cell lung cancer[J]. Zhonghua Shi Yong Zhong Xi Yi Za Zhi, 2005,18(6):873-876
[25] 周卫东, 徐振晔, 王中奇 , 等. 抗瘤增效方对NSCLC化疗患者免疫功能及血清VEGF、CYFRA21-1的影响[J]. 上海中医药杂志, 2005,39(3):6-8
Zhou WD, Xu ZY, Wang ZQ , et al. Effects of "Kangliu Zengxiao Decoction" on immunological functions and serum VEGF and CYFRA21-1 in patients with non-small cell lung cancer[J]. Shanghai Zhong Yi Yao Za Zhi, 2005,39(3):6-8
[26] 徐振晔, 朱晏伟, 周卫东 , 等. 双黄升白冲剂对化疗引起骨髓抑制的临床研究及小鼠骨髓超微结构的观察[J]. 中国中西医结合杂志, 2001,21(5):328-331
Xu ZY, Zhu YW, Zhou WD , et al. Clinical and experimental study on effect of Shuanghuang Shengbai granule on myelosuppression induced by chemotherapy and ultrastructure observation of bone marrow in mice[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2001,21(5):328-331
[27] 张晖, 王中奇, 徐振晔 , 等. 双黄升白冲剂治疗肺癌化疗骨髓抑制82例分析[J]. 中医药学刊, 2003,21(7):1162-1163
Zhang H, Wang ZQ, Xu ZY , et al. Treatment of chemotherapy-induced myelosuppression by Shuanghuang Shengbai Granules for patients with lung cancer: analysis of 82 cases[J]. Zhong Yi Yao Xue Kan, 2003,21(7):1162-1163
[28] 王中奇, 徐振晔 . 益气养精法治疗中晚期肺癌的探讨[J]. 上海中医药大学学报, 2002,16(4):30-31
Wang ZQ, Xu ZY . Exploration of "qi-benefiting and essence-nourishing method" in the treatment of pulmonary cancer in middle and late stage[J]. Shanghai Zhong Yi Yao Da Xue Xue Bao, 2002,16(4):30-31
[29] 刘城林, 陈为平, 崔书中 , 等. 参芪扶正注射液辅助化疗治疗老年非小细胞肺癌临床观察[J]. 中国中西医结合杂志, 2004,24(10):901-903
Liu CL, Chen WP, Cui SZ , et al. Effect of Shenqi Fuzheng injection for assistance of chemotherapy in treating senile patients with non-small cell lung cancer[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2004,24(10):901-903
[30] 赵兴 . 参芪扶正注射液减轻肿瘤放化疗毒副反应的临床观察[J]. 中国中西医结合杂志, 2004,24(9):857-858
Zhao X . Clinical study of Shenqi Fuzheng Injection in relieving side reactions of radio-chemotherapy for tumor[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2004,24(9):857-858
[31] 余胜珠, 杨光华, 冯金梅 . 参芪扶正注射液联合化疗治疗恶性肿瘤86例临床观察[J]. 中西医结合学报, 2006,4(1):84-86
Yu SZ, Yang GH, Feng JM . Clinical study on treatment of malignant neoplasms with Shenqi Fuzheng injection and chemotherapy[J]. Zhong Xi Yi Jie He Xue Bao, 2006,4(1):84-86
[32] 刘云霞, 匡唐洪, 蒋沈君 . 华蟾素注射液改善晚期癌症患者生活质量的临床观察[J]. 中国中医药科技, 2005,12(1):45-46
Liu YX, Kuang TH, Jiang SJ . Clinical observation of cinobufacini injection in improving quality of life for patients with malignant tumor[J]. Zhongguo Zhong Yi Yao Ke Ji, 2005,12(1):45-46
[33] 陈燕平, 刘秀娟 . 华蟾素注射液配合化疗治疗晚期恶性肿瘤临床观察[J]. 实用中西医结合临床, 2003,3(2):18
Chen YP, Liu XJ . Clinical observation of cinobufacini injection combined with chemotherapy in treating advanced malignant tumor[J]. Shi Yong Zhong Xi Yi Jie He Lin Chuang, 2003,3(2):18
[34] 臧爱华, 饶建华, 王志军 , 等. 康莱特在肺癌综合治疗中的作用[J]. 肿瘤防治研究, 2000,27(4):287-288
Zang AH, Rao JH, Wang ZJ , et al. The effect of Kang Lai-te injection and multimodality therapy in primary lung lancer.[J]. Zhong Liu Fang Zhi Yan Jiu, 2000,27(4):287-288
[35] 王宇岭, 李道明, 徐红 , 等. 康莱特注射液联合化疗治疗晚期非小细胞肺癌[J]. 癌症进展杂志, 2005,3(3):274-275
Wang YL, Li DM, Xu H , et al. Combination of Kanglaite injection and chemotherapy for treatment of advanced non-small cell lung cancer[J]. Ai Zheng Jin Zhan Za Zhi, 2005,3(3):274-275
[36] 张蕴萍 . 康莱特注射液治疗晚期肺癌的临床分析[J]. 现代肿瘤医学, 2003,11(3):237
Zhang YP.Clinical analysis of Kanglaite injection for treatment of advanced lung cancer[J].Xian Dai Zhong Liu Yi Xue, 2003, 11(3):237. Chinese
[1] Sherman Gu, Arthur Yin Fan. Controversial conclusions from two randomized controlled trials for acupuncture's effects on polycystic ovary syndrome or in vitro fertilization support. Journal of Integrative Medicine, 2020, 18(2): 89-91.
[2] Xue-qing Yu, Shu-guang Yang, Yang Xie, Jian-sheng Li. Traditional Chinese medicine in the treatment of idiopathic pulmonary fibrosis based on syndrome differentiation: Study protocol of exploratory trial. Journal of Integrative Medicine, 2020, 18(2): 163-168.
[3] Chang-quan Ling. Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2). Journal of Integrative Medicine, 2020, 18(2): 87-88.
[4] Wen Qiang Lee, Jeremy Teoh, Pei Zheng Kenneth Lee, Zhi Xiong Gerard Low, Xueling Sim, Foong Fong Mary Chong, Norbert Ludwig Wagner. Factors influencing communication of traditional Chinese medicine use between patients and doctors: a multisite cross-sectional study. Journal of Integrative Medicine, 2019, 17(6): 396-403.
[5] Mikhail Teppone. Medicine has always been “Modern” and “Scientific” from ancient times to the present day. Journal of Integrative Medicine, 2019, 17(4): 229-237.
[6] Charles Dalcanale Tesser, Ari Ojeda Ocampo Moré, Melissa Costa Santos, Emiliana Domingues Cunha da Silva, Fátima Terezinha Pelachini Farias, Lúcio José Botelho. Auriculotherapy in primary health care: A large-scale educational experience in Brazil. Journal of Integrative Medicine, 2019, 17(4): 302-309.
[7] Rachael Farrington, Ian F.Musgrave, Roger W.Byard. Evidence for the efficacy and safety of herbal weight loss preparations. Journal of Integrative Medicine, 2019, 17(2): 87-92.
[8] Fung-Kei Cheng. An overview of the contribution of acupuncture to thyroid disorders. Journal of Integrative Medicine, 2018, 16(6): 375-383.
[9] Chang-quan Ling, Jia Fan, Hong-sheng Lin, Feng Shen, Zhen-ye Xu, Li-zhu Lin, Shu-kui Qin, Wei-ping Zhou, Xiao-feng Zhai, Bai Li, Qing-hui Zhou, on behalf of the Chinese Integrative Therapy of Primary Liver Cancer Working Group. Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine. Journal of Integrative Medicine, 2018, 16(4): 236-248.
[10] Ashutosh Chauhan, Deepak Kumar Semwal, Satyendra Prasad Mishra, Ruchi Badoni Semwal. Ayurvedic concept of Shatkriyakala: A traditional knowledge of cancer pathogenesis and therapy. Journal of Integrative Medicine, 2017, 15(2): 88-94.
[11] Qing Ji, Yun-quan Luo, Wen-hai Wang, Xuan Liu, Qi Li, Shi-bing Su. Research advances in traditional Chinese medicine syndromes in cancer patients. Journal of Integrative Medicine, 2016, 14(1): 12-21.
[12] Bing He, Ge Zhang, Ai-ping Lu. Integrative network analysis: Bridging the gap between Western medicine and traditional Chinese medicine. Journal of Integrative Medicine, 2015, 13(3): 133-135.
[13] Zhao-guo Li, Xi-ru Liu. Comparative study on WHO Western Pacific Region and World Federation of Chinese Medicine Societies international standard terminologies on traditional medicine: Diseases of Paediatrics (Part 3). Journal of Integrative Medicine, 2015, 13(3): 201-204.
[14] Xiao Ye, Jing Wang. On English translation of infant Tuina points in traditional Chinese medicine. Journal of Integrative Medicine, 2015, 13(3): 205-207.
[15] Zhao-guo Li. Comparative study on WHO Western Pacific Region and World Federation of Chinese Medicine Societies international standard terminologies on traditional medicine: Diseases of Paediatrics (Part 2). Journal of Integrative Medicine, 2015, 13(2): 129-132.
Full text



[1] Jin-zhou Tian, Jing Shi, Xin-qing Zhang, Qi Bi, Xin Ma, Zhi-liang Wang, Xiao-bin Li, Shu-li Shen, Lin Li, Zhen-yun Wu, Li-yan Fang, Xiao-dong Zhao, Ying-chun Miao, Peng-wen Wang, Ying Ren, Jun-xiang Yin, Yong-yan Wang, Beijing United Study Group on MCI of the Capital Foundation of Medical Developments. An explanation on "guiding principles of clinical research on mild cognitive impairment (protocol)". Journal of Chinese Integrative Medicine, 2008, 6(1): 15-21
[2] Yi-ting He, Qing-lin Zha, Jian-ping Yu, Yong Tan, Cheng Lu, Ai-ping Lv. Principal factor analysis of symptoms of rheumatoid arthritis and their correlations with efficacy of traditional Chinese medicine and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 32-36
[3] Dong Yang, Yong-ping Du, Qing Shen, Wei Chen, Yan Yu, Guang-lei Chen. Expression of alpha-smooth muscle actin in renal tubulointerstitium in patients with kidney collateral stasis. Journal of Chinese Integrative Medicine, 2008, 6(1): 41-44
[4] SUN Ming-yu, ZUO Jian, DUAN Ji-feng, HAN Jun, FAN Shi-ming, ZHANG Wei, ZHU Li-fang, YAO Ming-hui. Antitumor activities of kushen flavonoids in vivo and in vitro. Journal of Chinese Integrative Medicine, 2008, 6(1): 51-59
[5] Hai-feng Wei, Bai-liu Ya, Ling Zhao, Cui-fei Ye, Li Zhang, Lin Li. Evaluation of tongue manifestation of blood stasis syndrome and its relationship with blood rheological disorder in a rat model of transient brain ischemia. Journal of Chinese Integrative Medicine, 2008, 6(1): 73-76
[6] Xi Lin, Jian-ping Liu. Tai chi for treating rheumatoid arthritis. Journal of Chinese Integrative Medicine, 2008, 6(1): 82
[7] Guo-hong Yuan, Xiao-jing Pang, He-chao Ma. Synergic effects of Danggui Buxue Decoction in reducing toxicity of cytoxan in tumor-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 83-88
[8] Li Zhou, Hong-xing Zhang, Ling-guang Liu, Wen-jun Wan. Effect of electro-acupuncture at Fenglong (GV 16) on nitric oxide and endothelin in rats with hyperlipidemia. Journal of Chinese Integrative Medicine, 2008, 6(1): 89-92
[9] Ning-qun Wang, Liang-duo Jiang, Zong-xing Li. Research progress in asthma-related quality of life. Journal of Chinese Integrative Medicine, 2008, 6(1): 93-97
[10] Jing-yuan Mao, Chang-xiao Liu, Heng-he Wang, Guang-li Wei , Zhen-peng Zhang, Jie Xing, Wang Xian liang , Ying-fei Bi . Effects of Shenmai Injection on serum concentration and pharmacokinetics of digoxin in dogs with heart failure. Journal of Chinese Integrative Medicine, 2010, 8(11): 1070-1074